| Literature DB >> 26749456 |
Andressa Barbosa1, Marcelo Dos Santos1, José Roberto Vasconcelos de Podestá2, Sônia Alves Gouvêa3, Sandra Ventorin Von Zeidler4, Iúri Drumond Louro1, Melissa de Freitas Cordeiro-Silva5.
Abstract
INTRODUCTION: Oral squamous cell carcinoma (OSCC) is a serious public health problem, due to its high mortality rate and worldwide rising incidence. OSCC susceptibility is mediated by interactions between genetic and environmental factors. Studies suggest that genetic variants encoding enzymes involved in folate metabolism may modulate OSCC risk by altering DNA synthesis/repair and methylation process.Entities:
Keywords: Carcinoma epidermoide oral; Cistationina beta-sintase; Cystathionine beta-synthase; Genetic polymorphism; Methylenetetrahydrofolate reductase; Metilenotetrahidrofolato redutase; Oral squamous cell carcinoma; Polimorfismo genético
Mesh:
Substances:
Year: 2015 PMID: 26749456 PMCID: PMC9444640 DOI: 10.1016/j.bjorl.2015.10.012
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Clinical characteristics of cancer patients and control subjects.
| Characteristics | Patients | Controls | |
|---|---|---|---|
| Female | 20 (19.8) | 20 (19.6) | 0.972 |
| Male | 81 (80.2) | 82 (80.4) | |
| ≤55 | 47 (46.5) | 56 (54.9) | 0.233 |
| >55 | 54 (53.5) | 46 (45.1) | |
| Whites | 22 (31.9) | – | – |
| “Pardos” (mixed race) | 32 (46.4) | – | |
| Blacks | 15 (21.7) | – | |
| Consumer | 73 (72.3) | 0 (0.0) | – |
| Non-consumer | 28 (27.7) | 0 (0.0) | |
| Unknown | 0 (0.0) | 102 (100.0) | |
| Early stage (I, II) | 25 (24.7) | – | – |
| Advanced (III, IV) | 76 (75.3) | – | |
| T1 | 12 (11.9) | – | – |
| T2 | 22 (21.8) | – | |
| T3 | 17 (16.8) | – | |
| T4 | 50 (49.5) | – | |
| N0 | 50 (49.5) | – | – |
| N+ | 51 (50.5) | – | |
| Well | 25 (24.7) | – | – |
| Moderately | 29 (28.7) | – | |
| Poorly | 5 (5.0) | – | |
| Not available | 42 (41.6) | – | |
| 101 (49.8) | 102 (50.2) | ||
Unknown (not considered in the statistical calculations).
Not available (not considered in the statistical calculations).
TNM classification.
Distribution of MTHFR and CBS genotypes among oral cancer patients and control groups.
| Genotypes | Total | Patients | Controls | |
|---|---|---|---|---|
| CC | 100 (49.2) | 50 (49.5) | 50 (49.0) | 0.438 |
| CT | 86 (42.4) | 45 (44.6) | 41 (40.2) | |
| TT | 17 (8.4) | 6 (5.9) | 11 (10.8) | |
| AA | 113 (55.7) | 60 (59.4) | 53 (52.0) | 0.541 |
| AC | 80 (39.4) | 36 (35.6) | 44 (43.1) | |
| CC | 10 (4.9) | 5 (5.0) | 5 (4.9) | |
| NN | 163 (80.3) | 76 (75.2) | 87 (85.3) | 0.112 |
| NI | 38 (18.7) | 24 (23.8) | 14 (13.7) | |
| II | 2 (1.0) | 1 | 1 | |
| Total | 203 (100.0) | 101 (49.8) | 102 (50.2) | |
N, non-insertion; I, insertion.
Distribution of MTHFR and CBS alleles among the oral cancer patients and control groups.
| Allele | Patients | Controls | |||||
|---|---|---|---|---|---|---|---|
| HWE | HWE | ||||||
| C | 145 (71.8) | 1.006 | 0.316 | 141 (69.1) | 0.348 | 0.555 | 0.556 |
| T | 57 (28.2) | 63 (30.9) | |||||
| A | 156 (77.2) | 0.018 | 0.893 | 150 (73.5) | 1.193 | 0.275 | 0.387 |
| C | 46 (22.8) | 54 (26.5) | |||||
| N | 176 (87.1) | 0.357 | 0.550 | 188 (92.2) | 0.260 | 0.610 | 0.096 |
| I | 26 (12.9) | 16 (7.8) | |||||
HWE, Hardy–Weinberg equilibrium; χ2, chi-square; N, non-insertion; I, insertion.
Linkage disequilibrium and haplotype analysis for alleles of C677T and A1298C polymorphisms.
| Haplotype | Cases | Controls | OR (95% CI) | ||
|---|---|---|---|---|---|
| C-A | 301 | 291 | – | – | 1 |
| C-C | 191 | 195 | 0.173 | 0.676 | 0.946 (0.817–1.364) |
| T-A | 231 | 213 | 0.141 | 0.706 | 1.048 (0.745–1.220) |
| T-C | 103 | 117 | 1.040 | 0.307 | 0.851 (0.861–1.602) |
Clinicopathological characteristics of patients with OSCC and relation with the MTHFR polymorphisms studied.
| Features | ||||||
|---|---|---|---|---|---|---|
| CC | CT | TT | CT + TT | |||
| Early stage (I, II) | 12 (24.0) | 11 (24.4) | 2 (33.3) | 0.880 | 13 (25.5) | 0.862 |
| Advanced (III, IV) | 38 (76.0) | 34 (75.6) | 4 (66.7) | 38 (74.5) | ||
| T1 | 5 (10.0) | 5 (11.1) | 2 (33.3) | 0.569 | 7 (13.7) | 0.716 |
| T2 | 12 (24.0) | 10 (22.2) | 0 (0.0) | 10 (19.6) | ||
| T3 | 10 (20.0) | 6 (13.3) | 1 (16.7) | 7 (13.7) | ||
| T4 | 23 (46.0) | 24 (53.3) | 3 (50.0) | 27 (52.9) | ||
| N0 | 19 (38.0) | 28 (62.2) | 3 (50.0) | 0.062 | 31 (60.8) | 0.022 |
| N+ | 31 (62.0) | 17 (37.8) | 3 (50.0) | 20 (39.2) | ||
| Well | 10 (20.0) | 15 (33.3) | 0 (0.0) | 0.192 | 15 (29.4) | 0.238 |
| Moderately | 12 (24.0) | 14 (31.1) | 3 (50.0) | 17 (33.3) | ||
| Poorly | 4 (8.0) | 1 (2.2) | 0 (0.0) | 1 (2.0) | ||
| Not available | 24 (48.0) | 15 (33.3) | 3 (50.0) | 18 (35.3) | ||
TNM classification.
Not available (not considered in the statistical calculations).
Clinicopathological characteristics of patients with OSCC and relation with the CBS polymorphism studied.
| Features | |||
|---|---|---|---|
| Non-insertion | Insertion | ||
| Early stage (I, II) | 18 (23.7) | 7 (28.0) | 0.664 |
| Advanced (III, IV) | 58 (76.3) | 18 (72.0) | |
| T1 | 8 (10.5) | 4 (16.0) | 0.792 |
| T2 | 18 (23.7) | 4 (16.0) | |
| T3 | 13 (17.1) | 4 (16.0) | |
| T4 | 37 (48.7) | 13 (52.0) | |
| N0 | 40 (52.6) | 10 (40.0) | 0.273 |
| N+ | 36 (47.4) | 15 (60.0) | |
| Well | 19 (25.0) | 6 (24.0) | 0.462 |
| Moderately | 22 (28.9) | 7 (28.0) | |
| Poorly | 5 (6.6) | 0 (0.0) | |
| Not available | 30 (39.5) | 12 (48.0) | |
TNM classification.
Not available (not considered in the statistical calculations).
Multivariate analysis of the nodal status, according to tumor size and MTHFR C677T polymorphism.
| Nodal status (N) | ||
|---|---|---|
| Variable | Multivariate analysis | |
| OR (95% CI) | ||
| T1, T2 | 1 | |
| T3 | 3.07 (0.87–10.87) | 0.083 |
| T4 | 6.46 (2.32–17.95) | <0.001 |
| CC | 1 | |
| CT + TT | 0.32 (0.13–0.77) | 0.012 |
OR, odds ratio; CI, confidence interval.
TNM classification.